- Previous Rank316
- Revenues ($M)30390
- Revenue Percent Change-6.9
- Profits ($M)13501
- Profits Percent Change-25.4
- Assets ($M)56977
- Employees9000
Gilead is known for its hepatitis C cures Sovaldi and Harvoni. But backlash to those drugs’ prices (among other problems) has contributed to the biotech giant’s 2016 slump. Gilead revenues fell nearly 7% to $30.4 billion in 2016 compared to the previous year. Some analysts have been urging the drug maker to make a major acquisition to shore up its experimental pipeline; but Gilead appears determined to invest in its own drug candidates by pumping money into R&D. And, in the meantime, it’s sitting on a massive bed of cash.
Company Information
CEO | John F. Milligan |
Sector | Health Care |
Industry | Pharmaceuticals |
HQ Location | Foster City, CA |
Website | www.gilead.com |
Years on Global 500 List | 3 |
Employees | 9,000 |
Key Financials (Last Fiscal Year)
Revenues ($M) | $30,390 |
Profits ($M) | $13,501 |
Assets ($M) | $56,977 |
Total Stockholder Equity ($M) | $18,887 |
Profit Ratios
Profit as % of Revenues | 44.4% |
Profits as % of Assets | 23.7% |
Profits as % of Stockholder Equity | 71.5% |